394735-17-2

Basic information

• Product Name: Ethyl 2-amino-3-cyclobutylpropanoate
• Synonyms: Ethyl 2-amino-3-cyclobutylpropanoate;2-AMino-3-cyclobutyl-propionic acid ethyl ester;Cyclobutanepropanoic acid, α-amino-, ethyl ester
• CAS NO: 394735-17-2
• Molecular Formula: C₉H₁₇NO₂
• Molecular Weight: 171.24
• Mol File: 394735-17-2.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 227.8 °C at 760 mmHg
• Flash Point: 95 °C
• Appearance: /
• Density: 1.034
• Vapor Pressure: 0.0761mmHg at 25°C
• Refractive Index: 1.478
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: Ethyl 2-amino-3-cyclobutylpropanoate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-amino-3-cyclobutylpropanoate(394735-17-2)
• EPA Substance Registry System: Ethyl 2-amino-3-cyclobutylpropanoate(394735-17-2)

Safety Data

• Hazardous Substances Data: 394735-17-2(Hazardous Substances Data)

Usage

General Description

Ethyl 2-amino-3-cyclobutylpropanoate is a chemical compound also referred to as 3-Cyclobutyl-2-aminopropanoic acid ethyl ester. This organic chemical falls into the category of alkyl-aryl compounds which possess a specific arrangement of carbon atoms in a cyclobutane, a type of cycloalkane structure along with an amino functional group and an ethyl ester group in its chemical structure. The combination of these functional groups provides the compound with its distinct chemical and physical properties. It is typically used for industrial purposes and in chemical research, however, specific details about its usage, toxicity, and safety measures are not widely known or documented.

InChI:InChI=1/C9H17NO2/c1-2-12-9(11)8(10)6-7-4-3-5-7/h7-8H,2-6,10H2,1H3

Upstream product

• 17247-58-4 (Bromomethyl)cyclobutane 
• 69555-14-2 ethyl N-diphenylmethylene glycine 
• 1025799-39-6 2-(benzhydrylidene-amino)-3-cyclobutyl-propionic acid ethyl ester 

Downstream Products

• 816430-02-1 ethyl 2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoate 
• 565456-74-8 C₉H₁₇NO₂*ClH 
• 1606172-09-1 benzyl 4-chloro-1-cyclobutyl-3-oxobutan-2-yl carbamate 
• 1606172-10-4 benzyl 4,4-dichloro-1-cyclobutyl-3-oxobutan-2-yl carbamate 
• 1606172-08-0 ethyl 2-(benzyloxycarbonylamino)-3-cyclobutyl propanoate 
• 565456-75-9 2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid 
• 394735-25-2 {(S)-2-[(1R,2S,5S)-2-(2-Carbamoyl-1-cyclobutylmethyl-2-hydroxy-ethylcarbamoyl)-6,6-dimethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxo-ethyl}-carbamic acid tert-butyl ester 
• 394735-28-5 (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicylo[3.1.0]-hexane-2-carboxamide 
• 1036931-36-8 3-amino-4-cyclobutyl-2-hydroxybutanamide hydrochloride 
• 394735-22-9 tert-butyl 4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-ylcarbamate 
• 394730-60-0 boceprevir 
• 394735-18-3 tert-butyl 3-cyclobutyl-1-(methoxy(methyl)amino)-1-oxopropan-2-ylcarbamate 
• 394735-20-7 (2-cyano-1-cyclobutylmethyl-2-hydroxyethyl)carbamic acid tert-butyl ester 
• 394735-19-4 (2-cyclobutyl-1-formylethyl)carbamic acid tert-butyl ester 

Relevant articles and documents

A New and convenient synthesis of the boceprevir P1 fragment, β-aminoα-hydroxy amide

A new and convenient synthesis of the P1 fragment of HCV inhibitor, boceprevir is described. This approach efficiently provides P1 fragment of boceprevir using simple and easy handling reagents suitable for scale up. This synthetic route involves the conversion of ester intermediate into novel intermediate, α-chloro ketone via chloroacetate Claisen condensation, followed by further simple conversions to β-amino-α-hydroxy amide, P1 fragment of boceprevir in high yield.

PROCESS FOR THE SYNTHESIS OF 3-AMINO-3-CYCLOBUTYLMETHYL-2-HYDROXYPROPIONAMIDE OR SALTS THEREOF

A process for preparing 3-amino-3-cyclobutylmethyl-2-hydroxypropionamide of the Formula I: [Chemical formula should be inserted here as it appears in the paper abstract.] or a salt thereof involves providing a compound of the Formula VI described herein in a solution comprising predominately dimethylsulfoxide (DMSO) and converting this compound directly to the compound of the Formula VIII described herein without working up or isolating the intermediate compound of the Formula VII described herein.

Administration of HCV protease inhibitors in combination with food to improve bioavailability

Methods of treating, preventing or ameliorating one or more symptoms of hepatitis C in a subject comprising the step of administering at least one HCV protease inhibitor in combination with food are provided. Also provided are methods of increasing bioavailability of an HCV protease inhibitor and methods of increasing serum levels of an HCV protease inhibitor in a subject. All methods comprise adminstering at least one HCV protease inhibitor in combination with food, the at least one HCV protease inhibitor selected from the group consisting of compounds of Formulae I-XXVI, described herein. Administration of compounds of the present invention in combination with food provides improved bioavailability and increased peak serum levels of the compounds as compared to administration without food.